EPHA2 and pancreatic neoplasm: We recently demonstrated that these agonistic agents strongly reduced BxPc3 pancreatic-cancer cell migration [29], and suppressed tumor metastases in an orthotopic model of EphA2-driven aggressive prostate cancer [30].